Just days after an upbeat R&D event, Neurocrine Biosciences has found itself having to report a phase 3 failure. The company’s Ingrezza (valbenazine), approved to treat certain uncontrolled movement ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results